Sign in
Active, not recruitingPhase 3

Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)

Key facts

Who runs it
University Health Network, Toronto
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
120 people, planned
Started
3 Nov 2025
Expected to end
30 Apr 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • H5N1 vaccine (Arepanrix, GSK)
  • Placebo
Record updated
23 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Age ≥ 18 and greater than 3 months post-transplant
  • Stable graft function
  • eGFR >30mL/min/1.73m2
  • Able to provide informed consent

Who cannot take part

  • Previous life-threatening reaction to influenza vaccine (ie Guillain Barré Syndrome)
  • Ongoing or recent therapy for acute rejection (within the previous 30 days)
  • Receiving treatment for active or acute infection
  • Allergy to vaccine components
  • Ongoing active cytomegalovirus (CMV) infection with viral load of greater or equal to 1000 international units/ml in the last 7 days
  • Febrile illness in the past 2 weeks
  • Diagnosis of influenza virus infection in the last 90 days
  • Rituximab in the last 6 months
  • Unable to provide informed consent
  • 2025 seasonal influenza vaccination in preceding 6 weeks
  • Recent other vaccination in last 14 days
  • Receipt of intravenous immunoglobulin in last 30 days or expected to receive in next 30 days; Life expectancy < 3 months
  • Pregnancy known at the time of enrolment

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Influenza is an important pathogen in transplant recipients. The current widespread outbreak of highly pathogenic H5N1 avian influenza (HPAI) in livestock, and the occurrence of several human cases of infection suggest that the next influenza pandemic may be soon approaching. Transplant patients will likely be uniquely predisposed to serious infection with high morbidity and mortality. There are a number of important reasons that evaluation of prevention strategies are critical in this highly vulnerable population. Currently, there is no data on the immunogenicity of H5Nx vaccines in this highly vulnerable population. The investigators plan to study the safety and immunogenicity of a two-dose regimen of the pandemic influenza H5N1 vaccine in organ transplant patients.

The 2 groups in the trial

  • H5N1 vaccineExisting treatment, for comparison

    This arm will receive 2 doses of approved H5N1 vaccine, 3 weeks apart

    Treatment: H5N1 vaccine (Arepanrix, GSK)

  • PlaceboPlacebo, for comparison

    This arm will receive 2 doses of normal saline (placebo), 3 weeks apart

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial): Safety and Immunogenicity of Pandemic Influenza Vaccine in Organ Transplant Recipients
Record updated
23 October 2026